UY34166A - Composición farmacéutica oftalmológica tópica que contiene regorafenib - Google Patents

Composición farmacéutica oftalmológica tópica que contiene regorafenib

Info

Publication number
UY34166A
UY34166A UY0001034166A UY34166A UY34166A UY 34166 A UY34166 A UY 34166A UY 0001034166 A UY0001034166 A UY 0001034166A UY 34166 A UY34166 A UY 34166A UY 34166 A UY34166 A UY 34166A
Authority
UY
Uruguay
Prior art keywords
typical
pharmaceutical composition
composition containing
ophthalmological pharmaceutical
containing regorafenib
Prior art date
Application number
UY0001034166A
Other languages
English (en)
Inventor
Boettger Dr Michael
Degenfeld Dr Georges
Freundlieb Dr Julia
Hirth-Dietrich Dr Claudia
Keldenich Dr Joerg
Klar Dr Juergen
Muenster Dr Uwe
Ohm Dr Andreas
Richter Dr Annett
Riedl Dr Bernd
Original Assignee
Bayer Pharma AG
Bayer Ip Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46456546&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UY34166(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Pharma AG, Bayer Ip Gmbh filed Critical Bayer Pharma AG
Publication of UY34166A publication Critical patent/UY34166A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts

Abstract

La presente invención se refiere a composiciones farmacéuticas oftalmológicas tópicas que contienen regorafenib, un hidrato, solvato o sal farmacéuticamente aceptable del mismo o un polimorfo del mismo y su procedimiento de preparación y su uso para el tratamiento de trastornos oftalmológicos.
UY0001034166A 2011-06-28 2012-06-27 Composición farmacéutica oftalmológica tópica que contiene regorafenib UY34166A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP11171719 2011-06-28
EP12155281 2012-02-14

Publications (1)

Publication Number Publication Date
UY34166A true UY34166A (es) 2013-01-31

Family

ID=46456546

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001034166A UY34166A (es) 2011-06-28 2012-06-27 Composición farmacéutica oftalmológica tópica que contiene regorafenib

Country Status (25)

Country Link
US (1) US20140296301A1 (es)
EP (1) EP2726059A1 (es)
JP (1) JP5998213B2 (es)
KR (1) KR20140048218A (es)
CN (1) CN103889399A (es)
AP (1) AP2013007335A0 (es)
AR (1) AR086800A1 (es)
AU (1) AU2012277905A1 (es)
BR (1) BR112013033831A2 (es)
CA (1) CA2840329A1 (es)
CL (1) CL2013003700A1 (es)
CO (1) CO6920289A2 (es)
CR (1) CR20130693A (es)
CU (1) CU24163B1 (es)
DO (1) DOP2013000314A (es)
EA (1) EA201400064A1 (es)
EC (1) ECSP13013106A (es)
GT (1) GT201300322A (es)
HK (1) HK1197176A1 (es)
MX (1) MX2013015287A (es)
PE (1) PE20141031A1 (es)
TN (1) TN2013000533A1 (es)
UY (1) UY34166A (es)
WO (1) WO2013000917A1 (es)
ZA (1) ZA201400646B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG155996A1 (en) 2004-09-29 2009-10-29 Bayer Schering Pharma Ag Thermodynamically stable form of bay 43-9006 tosylate
AR081060A1 (es) 2010-04-15 2012-06-06 Bayer Schering Pharma Ag Procedimiento para preparar 4-{4-[({[4-cloro-3-(trifluorometil)fenil]amino}carbonil)amino]-3-fluorofenoxi}-n-metilpiridin-2-carboxamida
UY35183A (es) * 2012-12-21 2014-07-31 Bayer Healthcare Llc Composición farmacéutica oftalmológica tópica que contiene regorafenib
WO2015011659A1 (en) * 2013-07-24 2015-01-29 Dr. Reddys Laboratories Limited Crystalline polymorphic forms of regorafenib and processes for the preparation of polymorph i of regorafenib
CN103923000A (zh) * 2014-01-29 2014-07-16 苏州晶云药物科技有限公司 几种新晶型及其制备方法
CN104546776B (zh) * 2015-02-10 2017-08-22 杭州朱养心药业有限公司 瑞戈非尼片剂药物组合物和制法
WO2016200688A1 (en) * 2015-06-06 2016-12-15 Cloudbreak Therapeutics, Llc Compositions and methods for treating pterygium
WO2017210130A1 (en) 2016-06-02 2017-12-07 Cloudbreak Therapeutics, Llc Compositions and methods of using nintedanib for improving glaucoma surgery success

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2732222B1 (fr) * 1995-03-28 1997-04-25 Oreal Utilisation d'un antagoniste de cgrp pour le traitement des prurits et des dysesthesies oculaires et palpebraux
SI1511516T1 (sl) * 2002-05-28 2009-06-30 Nycomed Gmbh Topično uporaben farmacevtski pripravek
UA84156C2 (ru) * 2003-07-23 2008-09-25 Байер Фармасьютикалс Корпорейшн Фторозамещённая омега-карбоксиарилдифенилмочевина для лечения и профилактики болезней и состояний
CN101175475B (zh) 2005-05-10 2010-04-14 爱尔康公司 包含活性成分、泊洛沙姆或美洛沙泊表面活性剂和二醇的混悬制剂、其用于生产治疗眼科病症的药物的用途
NZ563984A (en) 2005-06-08 2011-11-25 Targegen Inc Methods and compositions for the treatment of ocular disorders
MX2008006379A (es) 2005-11-29 2009-03-03 Smithkline Beecham Corp Metodo de tratamiento.
EP1962828A1 (en) * 2005-12-15 2008-09-03 Bayer HealthCare AG Diaryl urea for treating inflammatory skin, eye and/or ear diseases
US20070149593A1 (en) 2005-12-23 2007-06-28 Alcon, Inc. PHARMACEUTICAL FORMULATION FOR DELIVERY OF RECEPTOR TYROSINE KINASE INHIBITING (RTKi) COMPOUNDS TO THE EYE
WO2008027341A2 (en) 2006-08-30 2008-03-06 Merck & Co., Inc. Topical ophthalmic formulations
AR062927A1 (es) 2006-10-11 2008-12-17 Bayer Healthcare Ag 4- [4-( [ [ 4- cloro-3-( trifluorometil) fenil) carbamoil] amino] -3- fluorofenoxi) -n- metilpiridin-2- carboxamida monohidratada
RU2470635C2 (ru) * 2007-05-11 2012-12-27 Сантен Фармасьютикал Ко., Лтд. Профилактическое или терапевтическое средство, применяемое при заболеваниях заднего отдела глаза
DE102007055341A1 (de) * 2007-11-19 2009-05-20 Bayer Animal Health Gmbh Stabilisierung öliger Suspensionen enthaltend hydrophobe Kieselsäuren
CA2760687A1 (en) 2009-05-01 2010-11-04 Ophthotech Corporation Methods for treating or preventing ophthalmological diseases
WO2011009016A1 (en) 2009-07-16 2011-01-20 Glaxo Wellcome Manufacturing Pte Ltd Treatment method

Also Published As

Publication number Publication date
KR20140048218A (ko) 2014-04-23
CR20130693A (es) 2016-05-02
ZA201400646B (en) 2015-11-25
HK1197176A1 (en) 2015-01-09
GT201300322A (es) 2014-11-13
EA201400064A1 (ru) 2014-05-30
CL2013003700A1 (es) 2014-07-18
CN103889399A (zh) 2014-06-25
WO2013000917A1 (en) 2013-01-03
NZ619229A (en) 2016-04-29
DOP2013000314A (es) 2014-04-15
TN2013000533A1 (en) 2015-03-30
MX2013015287A (es) 2014-03-31
EP2726059A1 (en) 2014-05-07
CU20130168A7 (es) 2014-04-24
AU2012277905A8 (en) 2014-01-30
AP2013007335A0 (en) 2013-12-31
AR086800A1 (es) 2014-01-22
CU24163B1 (es) 2016-03-31
ECSP13013106A (es) 2014-01-31
CA2840329A1 (en) 2013-01-03
US20140296301A1 (en) 2014-10-02
AU2012277905A1 (en) 2014-01-16
BR112013033831A2 (pt) 2017-02-14
PE20141031A1 (es) 2014-08-21
CO6920289A2 (es) 2014-04-10
JP5998213B2 (ja) 2016-09-28
JP2014518233A (ja) 2014-07-28

Similar Documents

Publication Publication Date Title
GT201400063A (es) Benzilindazoles sustituidos para uso como inhibidores de la quinasa bub1 en el tratamiento de enfermedades hiperproliferativas
UY34166A (es) Composición farmacéutica oftalmológica tópica que contiene regorafenib
CY1120438T1 (el) Φαρμακευτικη συνθεση που περιλαμβανει μυο-ινοσιτολη και d-κιρο-ινοσιτολη
CR20140106A (es) Compuestos y composiciones como inhibidores de la quinasa c-kit
ECSP13013074A (es) Nuevos derivados de piridina
UY34414A (es) Composiciones hemostáticas
ECSP14013169A (es) Tableta a prueba de alteración que proporciona liberación inmediata del fármaco
UY34550A (es) Bencilpirazoles sustituidos
UY34365A (es) Compuestos heterociclicos
UY33958A (es) Inhibidores de la glucosilceramida sintasa
UY34165A (es) ?compuestos aldh-2 mitocondriales humanos para el tratamiento de la adicción?.
UY34472A (es) Derivados modificados de 4-fenil-piridina
CU20140081A7 (es) Nuevos derivados de pirrol, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
UY34779A (es) Anticuerpos anti-il-23 y composiciones farmacéuticas que los contienen
BR112015004936A2 (pt) composição farmacêutica revestida contendo regorafenib
CU20140095A7 (es) Nuevos derivados fosfatos, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
UY33930A (es) Inhibidores novedosos de quinasas
CR20140468A (es) Inhibidores de diacilglicerol aciltransferasa 2
CR20150204A (es) Nuevos derivados de piridina
BR112015012907A2 (pt) composição de cuidado pessoal
UY34415A (es) Composiciones hemostáticas
UY34800A (es) Combinaciones farmacéuticas que contienen un inhibidor de 11-beta-hidroxiesteroide dehidrogenasa-1 útil en trastornos metabólicos
UY34158A (es) Composicion herbicida
CO7151478A2 (es) Formulaciones estabilizadas que contienen anticuerpos anti-dll4
GT201500143A (es) Composiciones que comprenden vortioxetina y donepezilo campo tecnico

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20201020